Oxaliplatin was the third Pt-based anticancer drug to be clinically used worldwide. It exhibits
a broad spectrum of anticancer activity and was the first to be approved for the treatment of …

Transporters contribute to renal elimination of drugs; therefore drug disposition can be
impacted if transporters are inhibited by comedicant drugs. Regulatory agencies have …

The salt bridge is the strongest non-covalent interaction in nature and is known to participate
in protein folding, protein-protein interactions, and molecular recognition. However, the role …

Besides true acute kidney injury (AKI), the occurrence of pseudo-AKI has been associated
with several targeted agents. To improve the management of cancer patients treated with …

Introduction Select tyrosine kinase inhibitors (TKIs) used to treat oncogene-driven lung
cancers also inhibit MATE-1. When MATE-1 is blocked, creatinine is retained in the serum …

Dofetilide is a rapid delayed rectifier potassium current inhibitor widely used to prevent the
recurrence of atrial fibrillation and flutter. The clinical use of this drug is associated with …

Vincristine is a widely used chemotherapeutic drug for the treatment of multiple malignant
diseases that causes a dose-limiting peripheral neurotoxicity. There is no clinically effective …

Renal secretion plays an important role in excretion of drug from the kidney. Two major
transporters known to be highly involved in renal secretion are MATE1/2 K and OCT2, the …

Tyrosine kinase inhibitors (TKIs) decisively contributed in revolutionizing the therapeutic
approach to cancer, offering non-invasive, tolerable therapies for a better quality of life …

[177Lu] Lu-PSMA-617 has recently been successfully approved by the FDA, the MHRA,
Health Canada and the EMA as Pluvicto®. However, salivary gland (SG) and kidney …